March 6, 2022
1 min read

Pharma sector expected to grow between 6 and 8 % YoY in FY23

The agency said that higher Capex in lieu of the ‘Production-linked Incentives’ (PLI) scheme will restrict the quantum of free cash flow generation during the year….reports Asian Lite News

India’s pharmaceuticals market (IPM) is expected to grow between 6 and 8 per cent on a year-on-year (YoY) basis in FY23.

Accordingly, the growth has been capped due to high base effect and inventory stocking in FY21 on account of Covid-19-led disruption in supplies of key starting materials.

Besides, API (Active Pharmaceuticals Ingredient) businesses are expected to report high single-digit growth in FY23 due to a demand uptick, the overall revenue growth is expected at 9-to-10 per cent YoY.

In a research note, India Ratings and Research (Ind-Ra) said it has maintained a neutral outlook for the Indian pharmaceutical sector for FY23.

The agency said that higher Capex in lieu of the ‘Production-linked Incentives’ (PLI) scheme will restrict the quantum of free cash flow generation during the year.

pharma industry

“Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities,” the note said.

“Cost-cutting measures remain a priority for Indian companies. However, interim disruptions such as high raw material costs and logistic expenses will put pressure on the level of free cash flow generated.”

Besides, the agency said that with the significant improvement in the free cash flow generated in the near term, M&A activities will continue to provide inorganic push in FY23.

“Ind-Ra does not expect the sector’s liquidity to face a major risk, despite similar maturities levels in FY23 and FY24. Large pharma companies generally have large cash balances, which typically account for 14-16 per cent of their revenue.”

Furthermore, most companies have sufficient headroom under debt covenants and diversified funding sources.

“The interest coverage of large pharma players is likely to increase with scale and margin expansion.”

“Ind-Ra expects large pharma companies to continue with their healthy debt-funded capex and research and development programme, given higher visibility in terms of sales growth and profitability.”

ALSO READ: AYYA T1: Russian’s alternative to iPhone

Previous Story

Tesla receives environmental nod to produce EVs at Gigafactory Berlin

Next Story

Melbourne Cricket Ground to be renamed after Shane Warne

Latest from India News

Piyush Goyal Begins Europe Visit

As part of the visit, the minister will meet top leadership of major French companies such as Vicat, Total Energies, L’Oreal, Renault, Valeo, EDF and ATR….reports Asian Lite News Union Minister of

Colombia backs India on terror

The change in tone from Colombia is seen as diplomatically significant, especially given its forthcoming role as a non-permanent member of the United Nations Security Council (UNSC). In a diplomatic correction welcomed

UN Pays Tribute to Indian Soldiers

Thursday was observed as the 77th UN Peacekeepers Day, honouring the work of 61,353 peacekeepers, of whom 5,375 hailed from India….reports Asian Lite News Brigadier Amitabh Jha and Havildar Sanjay Singh, who
Go toTop

Don't Miss

Canada Probe Clears Modi, Jaishankar

The clarification came from Nathalie G. Drouin, Deputy Clerk of

 UAE explores labour market ties with India, Bangladesh

The meetings discussed bilateral relations, particularly in areas of labour